Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Operating Income: 2011-2025

Historic Operating Income for Fennec Pharmaceuticals (FENC) over the last 15 years, with Sep 2025 value amounting to -$189,000.

  • Fennec Pharmaceuticals' Operating Income rose 96.37% to -$189,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.7 million, marking a year-over-year decrease of 376.90%. This contributed to the annual value of $2.6 million for FY2024, which is 120.11% up from last year.
  • As of Q3 2025, Fennec Pharmaceuticals' Operating Income stood at -$189,000, which was up 93.08% from -$2.7 million recorded in Q2 2025.
  • Fennec Pharmaceuticals' Operating Income's 5-year high stood at $13.7 million during Q1 2024, with a 5-year trough of -$9.6 million in Q4 2022.
  • Moreover, its 3-year median value for Operating Income was -$1.8 million (2023), whereas its average is -$1.3 million.
  • Data for Fennec Pharmaceuticals' Operating Income shows a peak YoY increase of 360.78% (in 2024) and a maximum YoY decrease of 411.50% (in 2024) over the last 5 years.
  • Over the past 5 years, Fennec Pharmaceuticals' Operating Income (Quarterly) stood at -$4.2 million in 2021, then crashed by 89.29% to -$9.6 million in 2022, then spiked by 81.01% to -$1.8 million in 2023, then spiked by 48.62% to -$934,000 in 2024, then spiked by 96.37% to -$189,000 in 2025.
  • Its Operating Income was -$189,000 in Q3 2025, compared to -$2.7 million in Q2 2025 and -$808,000 in Q1 2025.